MedTrace Logo

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-10-29

No results posted yet for this study

Summary

The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:

Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.

Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.

AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo

Participants will:

* Take study drug or placebo for 12 weeks
* Stress Cardiac magnetic resonance imaging
* 12 lead electrocardiograms
* Complete questionnaires

Conditions

  • Angina Patients With Non-obstructive Coronary Artery Disease
  • Coronary Microvascular Disease
  • Coronary Microvascular Dysfunction (CMD)

Interventions

DRUG

Brezavvy 20Mg Oral Tablet

Brezavvy 20mg oral

DRUG

Placebo

Placebo tablet given to subject vs. active drug.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Patricia Rodriguez-Lozano, MD · Uni

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2026-03-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600178 on ClinicalTrials.gov